• Haktan Bağiş Erdem and Taha Bahsi.
• Department of Medical Genetics, University of Health Sciences, Dr. Abdurrahman Yurtaslan AnkaraOncology Training and Research Hospital, Ankara, Turkey
• Turk J Med Sci. 2020 Jun 23; 50 (4): 1015-1021.

Background/AimQuarter of colorectal cancer patients have a family history and 6% of these comprise hereditary cancer syndromes. For developing national health strategies for genetic screening, it is crucial to determine the spectrum of damaging alterations in causative genes and to describe frequent founder mutations.Materials And MethodsOne hundred and thirty six unrelated colorectal cancer cases were investigated. Qiagen large hereditary cancer panel and Hereditary Cancer Solution v1.1 panel were used for sequencing. The sequencing process was performed on the Illumina MiSeq system. The data analyses were performed on QIAGEN Clinical Insight (QCI™) Analyze software and Sophia DDM software.ResultsOf 136 patients, 11 (8%) were found to carry a pathogenic and 2 (1.4%) were found to carry a likely pathogenic mutation. Altogether, 12 different pathogenic and likely pathogenic mutations were detected.ConclusionThis study is the first study in Turkish colorectal cancer patients using next-generation sequencing. Point mutation screening in the families of patients with mutations will be able to identify individuals at risk in a cost-effective manner.This work is licensed under a Creative Commons Attribution 4.0 International License.

17 keywords...

hide…